Causes of Gender Dysphoria

1. Biological Factors

a. Genetic / Chromosomal

• Twin studies show higher concordance for transgender identity in monozygotic than dizygotic twins, suggesting a heritable component, though the specific genes involved have not been conclusively identified.
• Chromosomal anomalies (e.g., Klinefelter syndrome — 47,XXY) are associated with higher rates of gender variance.

b. Prenatal Hormone Exposure

• Congenital adrenal hyperplasia (CAH): Genetic females (46,XX) with CAH are exposed to excess androgens prenatally. They show increased rates of gender dysphoria, cross-gender behavior, and masculine gender identity — one of the strongest biological links in humans.
• Androgen insensitivity syndrome (AIS): Individuals with partial AIS have androgen receptors that are partially unresponsive. Despite XY chromosomes, they are typically raised as female and often identify as female, though gender dysphoria is more common in partial than complete AIS.
• 5-alpha reductase deficiency and 17-beta hydroxysteroid dehydrogenase-3 deficiency: Both result in undervirilized XY individuals raised as females who frequently shift to male identity at or after puberty, when testosterone surges.

c. Environmental Endocrine Disruptors

• In-utero exposure to phthalates (found in plastics) and polychlorinated biphenyls (PCBs) can disrupt fetal sex hormone signaling. Phthalates may elevate fetal testosterone, which has been linked to both autism spectrum disorder and GD.

d. Brain Neuroanatomy

• Several neuroimaging and postmortem studies have identified structural and functional brain differences in transgender individuals that more closely resemble the brain patterns of their experienced gender than their assigned sex:
  • The bed nucleus of the stria terminalis (BSTc) — a limbic region involved in sexual behavior — has been found to be female-typical in male-to-female transgender individuals in postmortem studies.
  • White matter microstructure and cortical thickness patterns in transgender individuals sometimes fall intermediate between cisgender males and females, or align with the experienced gender.
• A 2024 study found higher rates of minor physical anomalies (craniofacial variations that form during early fetal development) in individuals with GD vs. cisgender controls, supporting a neurodevelopmental prenatal origin.

e. Disorders of Sex Development (DSD)

2. Psychosocial Factors

a. Early Developmental Environment

• Gender identity formation begins very early: by age 2, most children can label adults by gender, and some show cross-gender identification as early as ages 2–3.
• Early work by John Money suggested a "sensitive period" ending around 27 months for gender identity consolidation via rearing practices — though subsequent research showed this window is not absolute.
• Infants as young as 9 months categorize gender-relevant attributes; by 18 months they associate gender labels with faces.

b. Family and Social Dynamics

• Psychoanalytic and attachment-based theories have proposed that early family dynamics, parental psychopathology, trauma, or disrupted attachment may contribute in some individuals.
• A subset of referred adolescents report trauma, abuse, or co-occurring mental health conditions as contextually relevant to their gender identity development, though causality is debated.

c. Social Contagion / Rapid-Onset Hypotheses

• Some researchers have proposed a "rapid-onset" subgroup, particularly in adolescent females, in which social and peer influences may play a role. This remains contested; critics argue it conflates late presentation with social causation.
• Social transition (affirmation of cross-gender identity) in young children has been associated with greater persistence of gender dysphoria in some longitudinal studies.

d. Co-occurring Psychopathology

• GD commonly co-occurs with anxiety, depression, autism spectrum disorder, ADHD, and PTSD — though whether these are causal, comorbid, or consequences of societal stigma and minority stress is unresolved.
• Minority stress model: Much of the psychiatric burden in transgender individuals is attributed to stigma, discrimination, family rejection, and lack of affirmation rather than GD itself.

3. Integrated Model

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry — Chapter 21.4, "Gender Identity, Gender Diversity, Gender Dysphoria/Incongruence" (Drescher & Byrne)
• StatPearls: Gender Dysphoria — NCBI Bookshelf
• NHS: Gender dysphoria

What Medical Science Actually Says About Transgender Care

What Major Medical Organizations Say

• Reduced rates of depression, anxiety, and suicidal ideation after affirming treatment in adults
• Gender dysphoria as a recognized diagnosis (DSM-5-TR, ICD-11)
• Evidence that social stigma and lack of affirmation — not gender identity itself — drive much of the psychiatric burden

Where the Evidence Is Weak — Especially in Youth

The Cass Review (UK, 2024)

• The evidence base for puberty blockers and cross-sex hormones in children and adolescents is "remarkably weak"
• Most studies had methodological flaws — no control groups, short follow-up, high dropout rates
• Long-term outcomes on bone density, fertility, brain development, and psychological wellbeing remain poorly characterized
• The NHS subsequently closed its main youth gender clinic (GIDS) and restricted puberty blockers

WHO and European Countries

• The WHO acknowledged in 2024 that "the evidence base for children and adolescents is limited and variable" and postponed its guidelines pending further review.
• Sweden, Finland, Norway, and Denmark have all restricted or significantly limited gender-affirming medical interventions in minors, citing insufficient evidence of benefit vs. risk.

Key Distinctions the Evidence Makes

The Honest Bottom Line

1. Recognizes gender dysphoria as real — it causes genuine, measurable distress
2. Supports adult gender-affirming care (hormones, surgery) with moderate evidence for mental health benefit
3. Remains genuinely uncertain about the risk-benefit balance of medical interventions in youth — and major European health systems have pulled back
4. Does not have consensus on youth treatment — this is an active, unresolved scientific debate, not a settled question
5. Is not a monolith — individual clinicians, researchers, and institutions hold varying positions based on the same evidence

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry — Chapter 21.4
• Miroshnychenko et al. (2025) — Puberty blockers systematic review [PMID 39855724]
• Ireland et al. (2025) — Adult outcomes systematic review [PMID 39973516]
• The Cass Review (NHS, 2024)